Interferon-alpha-2a biosimilar (Nanogen)

干扰素α-2a生物类似药 (Nanogen)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon-alpha-2a biosimilar (Nanogen)
Drug Alias Name干扰素α-2a生物仿制药 (Nanogen)Feronsure
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsFibrosisHepatitis CHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNanogen Biopharmaceutical Co
China Registration ClassN/A

Develop Information

Active CompaniesNanogen Biopharmaceutical Co
Inactive CompaniesN/A
Active IndicationsFibrosisHepatitis CHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeL03AB04
Related LinksN/A